Our project is exploring the remarkable potential of a specific type of immune cells, known as p16High immune cells, which we believe could play a vital role in managing and mitigating acute tissue damage and the effects of aging. Our research has shown that the COVID-19 mRNA vaccine, specifically the FDA-approved BNT162b2, effectively stimulates the production of these immune cells in both mice and humans. This reaction is crucial because these p16High cells are key to helping the body survive severe health threats such as sepsis, acute COVID-19 infections, and the impact of radiation exposure.

We are investigating how these cells contribute to creating a stronger, more resilient body environment that can tolerate diseases better. Our findings suggest that the mechanism behind this involves certain immune system responses that reduce inflammation and promote health.

Looking ahead, our project also examines how these immune cells can slow the deterioration of organs typically associated with aging, potentially leading to a longer, healthier life. This research not only helps us understand the body’s response to vaccines but also opens new pathways for enhancing disease resistance and extending health in later years. We hope this work will pave the way for new treatments that leverage the body’s own immune cells to fight disease and aging.

Publications from this project: